Tomefa E Asempa

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 29

Top Topics

Pseudomonas Aeruginosa

Urinary Tract Infection

Multidrug Resistant

Top Venues

The Journal of antimicrobial chemotherapy

Journal of clinical microbiology

JAC-antimicrobial resistance

Microbiology spectrum

This page only lists publications with an associated author ORCID identifier.

Publications

Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales. Journal of clinical microbiology 62 (6) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Tomefa E Asempa, Yasmeen Abouelhassan
Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition. JAC-antimicrobial resistance 6 (3) (2024)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, Yasmeen Abouelhassan
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Tomefa E Asempa, Abigail K Kois, Christian M Gill, Yasmeen Abouelhassan
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, Yasmeen Abouelhassan
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy 78 (3) (2023)
Tomefa E Asempa, Joseph L Kuti, Jeffrey C Nascimento, Samuel J Pope, Edward L Salerno, Patrick J Troy, David P Nicolau
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects. The Journal of antimicrobial chemotherapy (2023)
Tomefa E Asempa, Abigail K Kois, Christian M Gill, David P Nicolau
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. The Journal of antimicrobial chemotherapy (2023)
Aliaa Fouad, Christian M Gill, Patricia J Simner, Yasmeen Abouelhassan, Tomefa E Asempa
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians. The Journal of antimicrobial chemotherapy (2023)
Tomefa E Asempa, Abigail K Kois, Christian M Gill, David P Nicolau
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48. The Journal of antimicrobial chemotherapy 77 (10) (2022)
Abigail K Kois, David P Nicolau, Tomefa E Asempa
In vivo exposure-response relationship of meropenem against metallo-β-lactamase-harbouring Pseudomonas aeruginosa: an assessment using MICs from conventional and zinc-limited broth. The Journal of antimicrobial chemotherapy 77 (7) (2022)
Andrew J Fratoni, Lindsay M Avery, Yasmeen Abouelhassan, Tomefa E Asempa
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination. The Journal of antimicrobial chemotherapy (2022)
Tomefa E Asempa, Christian M Gill, Vindana Chibabhai, David P Nicolau
Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre). Microbiology spectrum 10 (2) (2022)
Yasmeen Abouelhassan, Andrew J Fratoni, Ashley K Shepard, David P Nicolau, Tomefa E Asempa
Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. The Journal of antimicrobial chemotherapy (2022)
Aliaa Fouad, Richard Quintiliani, Yasmeen Abouelhassan, Tomefa E Asempa
Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. The Journal of antimicrobial chemotherapy (2022)
Tomefa E Asempa, Hannah Bajor, Jessica H Mullins, Janice Hartnett, David P Nicolau
Evaluation of Metallo-β-Lactamase Susceptibility Testing in a Physiologic Medium. Microbiology spectrum (2021)
Tomefa E Asempa, Kamilia Abdelraouf, David P Nicolau
The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models. Antimicrobial agents and chemotherapy 65 (2) (2021)
Maxwell J Lasko, Tomefa E Asempa, David P Nicolau
Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. Antibiotics (Basel, Switzerland) 10 (2) (2021)
Maxwell J Lasko, David P Nicolau, Tomefa E Asempa
Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. The Journal of antimicrobial chemotherapy (2021)
Tomefa E Asempa, Kamilia Abdelraouf, David P Nicolau
Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs. Antimicrobial agents and chemotherapy 65 (6) (2021)
Tomefa E Asempa, Nicole A DeRosa, Cara Cassino, Dario Lehoux, Raymond Schuch, David P Nicolau
Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. The Journal of antimicrobial chemotherapy 76 (10) (2021)
Tomefa E Asempa, Sergey Izmailyan, Kenneth Lawrence, David P Nicolau
Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. Open forum infectious diseases 7 (12) (2020)
Anastasia Bilinskaya, Douglas J Buckheit, Michael Gnoinski, Tomefa E Asempa, David P Nicolau
Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae. Journal of clinical microbiology 58 (12) (2020)
Tomefa E Asempa, Lorita M Rebellato, Suzanne Hudson, Kimberly Briley, Angela Q Maldonado
Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clinical transplantation 32 (1) (2017)